← SynDRA
VIPADENANT
SynDRA canonical compound SYN0014257 — structure-anchored drug synonym record
| Clinical phase | Phase 1 |
|---|
| Primary target(s) | ADORA1 | ADORA2A | ADORA2B | ADORA3 |
|---|
| Mechanism of action | adenosine receptor antagonist |
|---|
All known targets
- ADORA2A
- ADORA1
- ADORA2B
- ADORA3
Mechanisms of action (all sources)
- ADORA2A ANTAGONIST
- Adenosine A2a receptor antagonist
- ADORA1 ANTAGONIST
- ADORA2B ANTAGONIST
- ADORA3 ANTAGONIST
- adenosine receptor antagonist
Cross-references
Synonyms
- BIIB014
- BIIB-014
- CEB-4520
- V-2006
- V2006
- VER-11135
- VER-A-00-11
- VER-A-00049
- VER-A00-11
- VER-A00049
- VER-ADO-49
- LDR3USH1NJ
- V 2006
- vipadenantum
- RefChem:901982
- DTXCID60118594
- MFCD12024697
- BIIB-014; CEB-4520
- Vipadenant [INN]
- UNII-LDR3USH1NJ
- Vipadenant [USAN:INN]
- Vipadenant?
- Vipadenant (USAN/INN)
- VIPADENANT [USAN]
- Vipadenant; BIIB-014
- VIPADENANT [WHO-DD]
- GTPL5612
- orb1305579
- SCHEMBL2849027
- SCHEMBL29359313
- SCHEMBL29421124
- C16H15N7O
- HQSBCDPYXDGTCL-UHFFFAOYSA-N
- GLXC-90428
- EX-A1029
- BIIB014; CEB-4520
- BDBM50254013
- AKOS026750454
Look up VIPADENANT in the interactive SynDRA portal →